 | Up a level |
Bühler, Silja; Jaeger, Veronika Katharina; Eperon, Gilles; Furrer, Hansjakob; Fux, Christoph A; Jansen, Stephanie; Neumayr, Andreas; Rochat, Laurence; Schmid, Sabine; Schmidt-Chanasit, Jonas; Staehelin, Cornelia; de Visser, Adriëtte W; Visser, Leonardus G; Niedrig, Matthias; Hatz, Christoph (2020). Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study1. Journal of travel medicine, 27(6) Oxford University Press 10.1093/jtm/taaa126
Veit, Olivia Stephanie; Domingo, Cristina; Niedrig, Matthias; Staehelin, Cornelia; Sonderegger, Beat; Delphine, Héquet; Stoeckle, Marcel; Calmy, Alexandra; Schiffer, Veronique; Bernasconi, Enos; Flury, Domenica; Hatz, Christoph; Zwahlen, Marcel; Furrer, Hansjakob (2018). Long-term immune response to yellow fever vaccination in HIV-infected individuals depends on HIV-RNA suppression status: Implications for vaccination schedule. Clinical infectious diseases, 66(7), pp. 1099-1108. Oxford University Press 10.1093/cid/cix960
Pas, Suzan D.; Patel, Pranav; Reusken, Chantal; Domingo, Cristina; Corman, Victor M.; Drosten, Christian; Dijkman, Ronald; Thiel, Volker Earl; Nowotny, Norbert; Koopmans, Marion P.G.; Niedrig, Matthias (2015). First international external quality assessment of molecular diagnostics for Mers-CoV. Journal of clinical virology, 69, pp. 81-85. Elsevier 10.1016/j.jcv.2015.05.022
Veit, Olivia; Niedrig, Matthias; Chapuis-Taillard, Caroline; Cavassini, Matthias; Mossdorf, Erik; Schmid, Patrick; Bae, Hi-Gung; Litzba, Nadine; Staub, Thomas; Hatz, Christoph; Furrer, Hansjakob (2009). Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clinical infectious diseases, 48(5), pp. 659-66. Cary, N.C.: The University of Chicago Press 10.1086/597006
